CCR1 antagonists in clinical development

Expert Opinion on Investigational Drugs

Volumn 14, Issue 7, 2005, Pages 785-796

  Pease, James E ^a   Horuk, Richard ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BAYER AG   (Germany)

Author keywords

Antagonism; CCR1; Chemokine receptors; Chemokines

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 2,2 DIPHENYL 5 [(4 CHLOROPHENYL)PIPERIDIN LYL]VALERONITRITE; 4,4' [CARBONYLBIS[IMINO 1H PYRROLE 4,2 DIYLCARBONYLIMINO(1 METHYL 1H PYRROLE 4,2 DIYL)CARBONYLIMINO]]BIS(1,7 NAPHTHALENESULFONIC ACID); AMINOOXYPENTANE RANTES; BX 513; CHEMOKINE RECEPTOR AFFECTING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CP 481715; CYCLOSPORIN; G PROTEIN COUPLED RECEPTOR; MLN 3897; N NONANOYL RANTES; UCB 35625; UNCLASSIFIED DRUG; XANTHENE 9 CARBOXAMIDE;

ALLERGIC DISEASE; CELL MIGRATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IC 50; KIDNEY FIBROSIS; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW;

ANIMALS; ARTHRITIS, RHEUMATOID; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; GRAFT REJECTION; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 22744448476     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.7.785     Document Type: Review

References (107)

1. ZLOTNIK A, YOSHIE O: Chemokines: a new classification system and their role in immunity. Immunity (2000) 12(2):121-127.
2. ROT A, VON ANDRIAN UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann. Rev. Immunol. (2004) 22:891-928.
3. GERARD C, ROLLINS BJ: Chemokines and disease. Nat. Immunol. (2001) 2(2):108-115.
4. CASCIERI MA, SPRINGER MS: The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curr. Opin. Chem. Biol. (2000) 4(4):420-427.
5. ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol. Sci. (2002) 23(10):459-467.
6. NEOTE K, DIGREGORIO D, MAK JY. HORUK R, SCHALL TJ: Molecular cloning, functional expression, and signalling characteristics of a C-C chemokine receptor. Cell (1993) 72(3):415-425.
7. GAO J-L, KUHNS DB, TIFFANY HL et al.: Structure and functional expression of the human macrophage inflammatory protein 1α/RANTES receptor. J. Exp. Med. (1993) 177(5):1421-1427.
8. MONTECLARO FS, CHARO IF: The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1α receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. (1996) 271(32):19084-19092.
9. PEASE JE, WANG J, PONATH PD, MURPHY PM: The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1α and eotaxin binding, respectively, but a second domain is essential for receptor activation. J. Biol. Chem. (1998) 273:19972-19976.
10. WONG M, FISH EN: RANTES and MIP-1α activate stats in T cells. J. Biol. Chem. (1998) 273(1):309-314.
11. GONG X, GONG W, KUHNS DB et al.: Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J. Biol. Chem. (1997) 272:11682-11685.
12. YOUN BS, ZHANG SM, LEE EK et al.: Molecular cloning of leukotactin- 1: a novel human β-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J. Immunol. (1997) 159:5201-5205.
13. SARAU HM, RUSH JA, FOLEY JJ et al.: Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function. J. Pharmacol. Exp. Ther. (1997) 283(1):411-418.
14. WEBER C, WEBER KS, KLIER C et al.: Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood (2001) 97(4):1144-1146.
15. EIS V, LUCKOW B, VIELHAUER V et al.: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J. Am. Soc. Nephrol. (2004) 15(2):337-347.
16. BROXMEYER HE, COOPER S, HANGOC G, GAO JL, MURPHY PM: Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J. Exp. Med. (1999) 189(12):1987-1992.
17. GAO JL, WYNN TA, CHANG Y et al.: Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med. (1997) 185(11):1959-1968.
18. GERARD C, FROSSARD JL, BHATIA M et al.: Targeted disruption of the β-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J. Clin. Invest. (1997) 100(8):2022-2027.
19. KASAMA T, STRIETER RM, STANDIFORD TJ, BURDICK MD, KUNKEL SL: Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1α. J. Exp. Med. (1993) 178:63-72.
20. THORNTON S, DUWEL LE, BOIVIN GP, MA Y, HIRSCH R: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. (1999) 42(6):1109-1118.
21. SZEKANECZ Z, HALLORAN MM, VOLIN MV et al.: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43(6):1266-1277.
22. KOCH AE, KUNKEL SL, HARLOW LA et al.: Macrophage inflammatory protein-1α. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J. Clin. Invest. (1994) 93(3):921-928.
23. HATANO Y, KASAMA T, IWABUCHI H et al.: Macrophage inflammatory protein 1α expression by synovial fluid neutrophils in rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(5):297-302.
24. + T lymphocytes into inflamed joints of rheumatoid arthritis. Int. Immunol. (1999) 11(4):553-559.
25. MACCHIONI P, BOIARDI L, MELICONI R et al.: Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. J. Rheumatol. (1998) 25(2):320-325.
26. LISIGNOLI G, TONEGUZZI S, POZZI C et al.: Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin. Exp. Immunol. (1999) 116(2):371-378.
27. BARNES DA, TSE J, KAUFHOLD M et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest. (1998) 101(12):2910-2919.
28. BALASHOV KE, ROTTMAN JB, WEINER HL, HANCOCK WW: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA (1999) 96(12):6873-6878.
29. McMANUS C, BERMAN JW, BRETT FM et al.: MCP-1, MCP-2 nd MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J. Neuroimmunol. (1998) 86(1):20-29.
30. + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. (2001) 159(5):1701-1710.
31. TREBST C, STAUGAITIS SM, TUCKY B et al.: Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol. Appl. Neurobiol. (2003) 29(6):584-595.
32. KIVISAKK P, TREBST C, LIU Z et al.: T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol. (2002) 129(3):510-518.
33. RAJAN AJ, ASENSIO VC, CAMPBELL IL, BROSNAN CF: Experimental autoimmune encephalomyelitis on the SJL mouse: effect of γ-δ T cell depletion on chemokine and chemokine receptor expression in the central nervous system. J. Immunol (2000) 164(4):2120-2130.
34. FISCHER FR, SANTAMBROGIO L, LUO Y et al.: Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. J. Neuroimmunol. (2000) 110(1-2):195-208.
35. ROTTMAN JB, SLAVIN AJ, SILVA R et al.: Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol (2000) 30(8):2372-2377.
36. ADAMS DH, HUBSCHER S, FEAR J et al.: Hepatic expression of macrophage inflammatory protein-1α and macrophage inflammatory protein-1β after liver transplantation. Transplantation (1996) 61(5):817-825.
37. FAIRCHILD RL, VANBUSKIRK AM, KONDO T, WAKELY ME, OROSZ CG: Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation (1997) 63(12):1807-1812.
38. FARVER CF, RAYCHAUDHURI B, MALUR A et al.: Increased alveolar macrophage nuclear factor-κB activation and macrophage inhibitory protein-1α levels in lung transplant patients. Transplantation (2000) 70(11):1599-1603.
39. PATTISON J, NELSON PJ, HUIE P et al.: RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet (1994) 343(8891):209-211.
40. PATTISON JM, NELSON PJ, HUIE P, SIBLEY RK, KRENSKY AM: RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant. (1996) 15(12):1194-1199.
41. AZZAWI M, HASLETON PS, GERAGHTY PJ et al.: RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. J. Heart Lung Transplant. (1998) 17(9):881-887.
42. BELPERIO JA, BURDICK MD, KEANE MP et al.: The role of the CC chemokine, RANTES, in acute lung allograft rejection. J. Immunol (2000) 165(1):461-472.
43. GAO W, TOPHAM PS, KING JA et al.: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest. (2000) 105(1):35-44.
44. TERAN LM, NOSO N, CARROLL M et al.: Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J. Immunol. (1996) 157:1806-1812.
45. POWELL N, HUMBERT M, DURHAM SR et al.: Increased expression of mRNA encoding RANTES and MCP-3 in the bronchial mucosa in atopic asthma. Eur. Respir. J. (1996) 9(12):2454-2460.
46. BERKMAN N, KRISHNAN VL, GILBEY T et al.: Expression of RANTES mRNA and protein in airways of patients with mild asthma. Am. J. Respir. Crit. Care Med. (1997) 154:1804-1811.
47. HOLGATE ST, BODEY KS, JANEZIC A et al.: Release of RANTES, MIP-1α, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. J. Respir. Crit. Care Med. (1997) 156(5):1377-1383.
48. RAJAKULASINGAM K, HAMID Q, O'BRIEN F et al.: RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am. J. Respir. Crit. Care Med. (1997) 155:696-703.
49. ALAM R, YORK J, BOYARS M et al.: Increased MCP-1, RANTES, and MIP-1α in bronchoalveolar lavage fluid of allergic asthmatic patients. Am. J. Respir. Crit. Care Med. (1996) 153(4 Part 1):1398-1404.
50. TILLIE-LEBLOND I, HAMMAD H, DESURMONT S et al.: CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. Am. J. Respir. Crit. Care Med. (2000) 162(2 Part 1):586-592.
51. KRAMER MF, OSTERTAG P, PFROGNER E, RASP G: Nasal IL-16 and MIP-1α in late-phase allergic response. Allergy Asthma Proc. (2001) 22(3):127-132.
52. BENSCH GW, NELSON HS, BORISH LC: Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann. Allergy Asthma Immunol. (2002) 88(5):457-462.
53. KABURAGI Y, SHIMADA Y, NAGAOKA T et al.: Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1α, MIP-1β, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol. Res. (2001) 293(7):350-355.
54. TEDLA N, WANG HW, McNEIL HP et al.: Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)-1α and MIP-1β. J. Immunol. (1998) 161(10):5663-5672.
55. SABROE I, HARTNELL A, JOPLING LA et al.: Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J. Immunol. (1999) 162(5):2946-2955.
56. PHILLIPS R, STUBBS VE, HENSON MR, WILLIAMS TJ, PEASE JE, SABROE I: Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter. J. Immunol. (2003) 170(12):6190-6201.
57. CAMPBELL EM, KUNKEL SL, STRIETER RM, LUKACS NW: Temporal role of chemokines in a murine model of cockroach Allergen-induced airway hyperreactivity and eosinophilia. J. Immunol. (1998) 161(12):7047-7053.
58. GONZALO J-A, LLOYD CM, WEN D et al.: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airways hyperresponsiveness. J. Exp. Med. (1998) 188(1):157-167.
59. -/- mice during chronic fungal allergic airway disease. J. Immunol. (2000) 165(3):1564-1572.
60. LAFFARGUE M, CALVEZ R, FINAN P et al.: Phosphoinositide 3-kinase-γ is an essential amplifier of mast cell function. Immunity (2002) 16(3):441-451.
61. TODA M, DAWSON M, NAKAMURA T et al.: Impact of engagement of Fcε RI and CC chemokine receptor 1 on mast cell activation and motility. J. Biol. Chem. (2004) 279(46):48443-48448.
62. MIYAZAKI D, NAKAMURA T, TODA M et al.: Macrophage inflammatory protein-1α as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J. Clin. Invest. (2005) 115(2):434-442.
63. PROUDFOOT AE, POWER CA, HOOGERWERF AJ et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. (1996) 271:2599-2603.
64. PROUDFOOT AE, BUSER R, BORLAT F et al.: Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Mol. Chem. (1999) 274(45):32478-32485.
65. MATSUI M, WEAVER J, PROUDFOOT AE et al.: Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J. Neuroimmunol. (2002) 128(1-2):16-22.
66. GRONE HJ, WEBER C, WEBER KS et al.: Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. (1999) 13(11):1371-1383.
67. STOJANOVIC T, BEDKE J, GRONE HJ et al.: Met-RANTES inhibition of mucosal perfusion failure in acute intestinal transplant rejection - role of endothelial cell-leukocyte interaction. J. Vasc. Res. (2002) 39(1):51-58.
68. BEDKE J, STOJANOVIC T, GRONE HJ et al.: Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant. Proc. (2002) 34(3):1049.
69. SONG E, ZOU H, YAO Y et al.: Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. (2002) 61(2):676-685.
70. YUN JJ, WHITING D, FISCHBEIN MP et al.: Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation (2004) 109(7):932-937.
71. VEILLARD NR, KWAK B, PELLI G et al.: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Re.s (2004) 94(2):253-261.
72. AJUEBOR MN, HOGABOAM CM, KUNKEL SL, PROUDFOOT AE, WALLACE JL: The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J. Immunol. (2001) 166(1):552-558.
73. BONVILLE CA, LAU VK, DELEON JM et al.: Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol. (2004) 78(15):7984-7989.
74. BHATIA M, PROUDFOOT AE, WELLS TN et al.: Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis. Br. J. Surg. (2003) 90(6):698-704.
75. ANDERS HJ, FRINK M, LINDE Y et al.: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J. Immunol. (2003) 170(11):5658-5666.
76. PANZER U, SCHNEIDER A, WILKEN J et al.: The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int. (1999) 56(6):2107-2115.
77. CHVATCHKO Y, PROUDFOOT AE, BUSER R et al.: Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J. Immunol. (2003) 171(10):5498-5506.
78. ELSNER J, MACK M, BRUHL H et al.: Differential activation ofCC chemokine receptors by AOP-RANTES. J. Biol. Chem. (2000) 275(11):7787-7794.
79. MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215-1224.
80. HESSELGESSER J, NG HP, LIANG M et al.: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. (1998) 273(25):15687-15692.
81. RICHELSON E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J. Clin. Psychiatry (1996) 57(Suppl 11):4-11.
82. CUSACK B, NELSON A, RICHELSON E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl.) (1994) 114(4):559-565.
83. LIANG M, MALLARI C, ROSSER M et al.: Identification and characterzation of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem. (2000) 275(25):19000-19008.
84. ANDERS HJ, VIELHAUER V, FRINK M et al.: A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. (2002) 109(2):251-259.
85. GLADUE RP, TYLASKA LA, BRISSETTE WH et al.: CP-481715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. (2003) 278(42):40473-40480.
86. HORUK R, SHUREY S, NG HP et al.: CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol. Lett (2001) 76(3):193-201.
87. HORUK R, CLAYBERGER C, KRENSKY AM et al.: A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem. (2001) 276(6):4199-4204.
88. NAYA A, SAGARA Y, OHWAKI K et al.: Design, synthesis, and discovery of a novel CCR1 antagonist. J. Med. Chem. (2001) 44(9):1429-1435.
89. NAYA A, ISHIKAWA M, MATSUDA K et al.: Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg. Med. Chem. (2003) 11(6):875-884.
90. SABROE I, PECK MJ, VAN KEULEN B et al.: A small molecule antagonist of the chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. (2000) 275(34):25985-25992.
91. DE MENDONCA FL, DA FONSECA PC, PHILLIPS RM et al.: Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem. (2005) 280(6):4808-4816.
92. BLANPAIN C, DORANZ BJ, BONDUE A et al.: The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. (2003) 278(7):5179-5187.
93. KATH JC, DIRICO AP, GLADUE RP et al.: The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. Bioorg. Med. Chem. Lett. (2004) 14(9):2163-2167.
94. KATH JC, BRISSETTE WH, BROWN MF et al.: Potent small molecule CCR1 antagonists. Bioorg. Med. Chem. Lett. (2004) 14(9):2169-2173.
95. BROWN MF, AVERY M, BRISSETTE WH et al.: Novel CCR1 antagonists with improved metabolic stability. Bioorg. Med. Chem. Lett. (2004) 14(9):2175-2179.
96. SALCEDO R HO, OPPENHEIM JJ, WELNIAK LA, BLAZAR BR, MURPHY WJ: Drug Inhibition of graft-versus-host disease by a distamycin analogue that interferes with chemokine receptor function. Blood (1999) 94(10 Suppl. 1):(Abstract 1738).
97. ONUFFER J, McCARRICK MA, DUNNING L et al.: Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. J. Immunol. (2003) 170(4):1910-1916.
98. SCHWARZ MK, WELLS TN: New therapeutics that modulate chemokine networks. Nat. Rev. Drug Discov. (2002) 1(5):347-358.
99. GARCIA-RAMALL E, MARQUES T, PRATS N et al.: Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J. Immunol (2002) 169(11):6467-6473.
100. OFFORD R: Peptides - The Wave of the Future (Part II) - Optimization of a superactive anti-HIV compound. Second International and 17th American Peptide Symposium, CA, USA, June 9 - 14 (2001).
101. HORUK R: Society for Medicines Research - Chemokine Receptors and Drug Discovery, Horsham, UK, March 11 (2004).
102. LAROSA G: BPS Winter Meeting - Chemokine Antagonists - Future Selective Therapy for Infection, Inflammation, Asthma, Allergy, Cancer and Transplantation, London, UK, December 17 (2001).
103. RICE WG TJ, HUANG M, HOWARD OMZ, MICHEJDA CJ, BADER JP: New Types of anti-HIV agents identified by the NCI Drug Discovery Program. 11th International Conference on Antiviral Research, San Diego, CA, USA, April 5 - 10 (1998).
104. GLADUE RP: Discovery and characterization of a novel CCR1 antagonist, CP-481715. Inflammation Research Association Conference - Chemokines: Latest Advances and Clinical Outcomes, Boston, MA, USA, February 26 - 27 (2004).
105. GODESSART N: CCR1 blockade in murine models of acute and chronic inflammation. Inflammation Research Association - 11th National Conference (Part VI), Bolton Landing, NY, USA. October 6 - 10 (2002).
106. 18F-Labelling of the CCR1 antagonist ZK-811460 for the diagnosis of Alzheimer's disease. Technical Exchange Meeting on Alzheimer Imaging, Berlin, Germany. October 30 (2003).
107. BAUMAN J: CCR1 antagonists. Frontiers in Medicinal Chemistry - Annual Meeting Erlangen, Germany. March 15 - 17 (2004).